- Home
- A-Z Publications
- Recent Patents on Nanotechnology
- Fast Track Listing
Recent Patents on Nanotechnology - Online First
Description text for Online First listing goes here...
-
-
From Solid to Fluid: Novel Approaches in Neuromorphic Engineering
Authors: Daniil Nikitin, Hynek Biederman and Andrei ChoukourovAvailable online: 18 October 2024More LessNeuromorphic engineering is rapidly developing as an approach to mimicking processes in brains using artificial memristors, devices that change conductivity in response to the electrical field (resistive switching effect). Memristor-based neuromorphic systems can overcome the existing problems of slow and energy-inefficient computing that conventional processors face. In the Introduction, the basic principles of memristor operation and its applications are given. The history of switching in sandwich structures and granular metals is reviewed in the Historical Overview. Particular attention is paid to the fundamental articles from the pre-memristor era (the 1960s-70s), which demonstrated the first evidence of resistive switching and predicted the filamentary mechanism of switching. Multi-dimensionality in neuromorphic systems: Despite the powerful computational abilities of traditional memristor arrays, they cannot repeat many organizational characteristics of biological neural networks, i.e., their multi-dimensionality. This part reviews the unconventional nanowire- and nanoparticle-based neuromorphic systems that demonstrate incredible potential for use in reservoir computing due to the unique spiking change in conductance similar to firing in neurons. Liquid-based neuromorphic devices: The transition of neuromorphic systems from solid to liquid state broadens the possibilities for mimicking biological processes. In this section, ionic current memristors are reviewed and, the working principles of which bring us closer to the mechanisms of information transmittance in real synapses. Nanofluids: A novel direction in neuromorphic engineering linked to the application of nanofluids for the formation of reconfigurable nanoparticle networks with memristive properties is given in this section. The Conclusion t summarizes the bullet points of the Review and provides an outlook on the future of liquid-state neuromorphic systems.
-
-
-
Formulation Optimization and Evaluation of Patented Solid Lipid Nanoparticles of Ambrisentan for Pulmonary Arterial Hypertension
Authors: Harshada Shewale and Abhishek KanugoAvailable online: 01 October 2024More LessBackgroundAmbrisentan is a new endothelin receptor antagonist extensively used to manage pulmonary or pulmonary arterial hypertension.
ObjectiveThe therapeutic efficacy of Ambrisentan is limited due to its reduced solubility, higher log P (3.4), and thus less bioavailability. The recent investigation was concentrated on the improvement of solubility, and bioavailability of Ambrisentan for the therapy of hypertension via solid lipid nanoparticles (SLN) administered orally.
MethodsXRD evaluated the compatibility of Ambrisentan with lipids with FTIR, DSC, and crystalline nature. The SLN was developed by High-pressure homogenization method. The Glyceryl monostearate and Tween 80 indicated the highest solubility, hence selected. The optimization was performed with Box-Behnken Design considering the concentration of GMS (X1), Tween 80 (X2), stirring speed (X3) as independent factors and particle size (Y1), entrapment efficiency (Y2) as dependent factors. The Patents on the SLN are Indian 202321053691, U.S. Patent, 10,973,798B2, U.S. Patent 10,251,960B2, U.S. Patent 2021/0069121A1 and U.S. Patent 2022/0151945A1.
ResultsThe optimized batch F1 showed particle size (130 nm), ZP (-18.9 mV), and entrapment efficiency (85.73%). The dual release pattern (prompt and sustained) was achieved with the SLN-loaded Ambrisentan for about 24 hours. The lyophilized sample was subjected to SEM, which also revealed a spherical shape of a colloidal dispersion with a particle size of 126 nm. Hence, the F1 batch is highly recommended for solid oral delivery and also for the pilot-plant scale-up.
ConclusionA marked improvement in the solubility and dissolution of Ambrisentan was attained with the SLN. Moreover, the sustained delivery via the oral route enabled the patient's comfort, compliance, and therapeutic efficacy.
-